J. Thompson

Publications526
h-index78
Citations34,262
Highly Influential Citations1,020
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • J. Wolchok
  • 667 Publications, 91,183 Citations
  • D. Schadendorf
  • 1,269 Publications, 84,724 Citations
  • S. Rosenberg
  • 1,424 Publications, 164,522 Citations
  • F. S. Hodi
  • 482 Publications, 43,895 Citations
  • Publications
  • Influence
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
PURPOSE A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-alpha) in progression-free survival (primary end point) as first-line treatment for metastatic… Expand
  • 1,885
  • 119
  • PDF
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.
PURPOSE To revise the staging system for cutaneous melanoma under the auspices of the American Joint Committee on Cancer (AJCC). MATERIALS AND METHODS The prognostic factors analysis described in… Expand
  • 2,547
  • 105
  • PDF
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.
PURPOSE The American Joint Committee on Cancer (AJCC) recently proposed major revisions of the tumor-node-metastases (TNM) categories and stage groupings for cutaneous melanoma. Thirteen cancer… Expand
  • 2,203
  • 82
Phase 3 trial of everolimus for metastatic renal cell carcinoma
A phase 3 trial demonstrated superiority at interim analysis for everolimus over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on vascular endothelial growth factor… Expand
  • 1,024
  • 59
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICPi)… Expand
  • 960
  • 49
  • PDF
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells
Adoptive T cell therapy, involving the ex vivo selection and expansion of antigen-specific T cell clones, provides a means of augmenting antigen-specific immunity without the in vivo constraints that… Expand
  • 1,199
  • 36
  • PDF
The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.
Three different syndromes produced by congeners of morphine have been identified in the nondependent chronic spinal dog. These syndromes have been attributed to interaction of agonists with three… Expand
  • 2,767
  • 33
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has… Expand
  • 630
  • 32
Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts.
Inflammatory processes in chronic rejection remain a serious clinical problem in organ transplantation. Activated cellular infiltrate produces high levels of both superoxide and nitric oxide. These… Expand
  • 723
  • 21
  • PDF
Decreased Zinc Affinity of Amyotrophic Lateral Sclerosis‐Associated Superoxide Dismutase Mutants Leads to Enhanced Catalysis of Tyrosine Nitration by Peroxynitrite
Abstract: Mutations to Cu/Zn superoxide dismutase (SOD) linked to familial amyotrophic lateral sclerosis (ALS) enhance an unknown toxic reaction that leads to the selective degeneration of motor… Expand
  • 452
  • 20